Heart failure & cardiomyopathies

Efficacy and Safety of Angiotensin Receptor–Neprilysin Inhibition in Heart Failure Patients with End-Stage Kidney Disease on Maintenance Dialysis: A Systematic Review and Meta-Analysis

Eur J Heart FailPublished Systematic review and meta-analysis

Pooled result · LVEFResult — go to the resultMean difference 4.03 % 95% CI 2.90–5.16

Authors' conclusion

This meta-analysis provided insights into the benefits of ARNI in HF patients with ESKD undergoing dialysis by improving left ventricular function, reversing left ventricular remodelling, and reducing the risk of all-cause mortality, without increasing the risk of HF hospitalizations, severe hyperkalaemia, and symptomatic hypotension.

Study context

Population
Heart failure (HF) patients with end-stage kidney disease on maintenance dialysis
Participants
2,494 patients26 studies
Comparison
Angiotensin receptor-neprilysin inhibitor (ARNI) vs conventional treatment
Outcome
LVEF
Methodological detailsrandom effects model
  • Random effects model

Pooled result

As reported in the abstract

Mean difference

4.03 %

95% CI 2.90–5.16

ARNIvs Conventional
mean difference 4.03 % (95% CI 2.90–5.16)
Left ventricular ejection fraction (LVEF) mean change before vs after ARNI
8.05% (95% CI 5.57-10.54)

Further pooled results

OutcomeRR (95% CI)P value
All-cause mortality0.64 (0.45–0.92)P = 0.01
HF hospitalization0.71 (0.43–1.18)P = 0.19

LV end-systolic diameter, LV mass index, left atrial diameter, E/e' ratio

Improved with ARNI
P < 0.05

Safety

Severe hyperkalaemia risk not significantly increased
P = 0.33
Symptomatic hypotension risk not significantly increased
P = 0.53

Original publication

Efficacy and Safety of Angiotensin Receptor–Neprilysin Inhibition in Heart Failure Patients with End-Stage Kidney Disease on Maintenance Dialysis: A Systematic Review and Meta-Analysis. Eur J Heart Fail. Published 9 September 2024. doi:10.1002/ejhf.3454

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.